The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
暂无分享,去创建一个
[1] A. Lamond,et al. The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway , 2016, Oncogene.
[2] M. Maris,et al. Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study , 2015, British journal of haematology.
[3] D. Xirodimas,et al. Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic. , 2015, Endocrine-related cancer.
[4] M. Peter,et al. Protein neddylation: beyond cullin–RING ligases , 2014, Nature Reviews Molecular Cell Biology.
[5] Shelly C. Lu,et al. Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer , 2014, Oncotarget.
[6] Q. Gao,et al. Overactivated neddylation pathway as a therapeutic target in lung cancer. , 2014, Journal of the National Cancer Institute.
[7] S. Sorrells,et al. Analysis of Apoptosis in Zebrafish Embryos by Whole-mount Immunofluorescence to Detect Activated Caspase 3 , 2013, Journal of visualized experiments : JoVE.
[8] A. Thompson,et al. p53-Based cyclotherapy: exploiting the ‘guardian of the genome' to protect normal cells from cytotoxic therapy , 2013, British Journal of Cancer.
[9] Ingeborg M. M. van Leeuwen. Cyclotherapy: opening a therapeutic window in cancer treatment , 2012, Oncotarget.
[10] S. Laín,et al. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells , 2012, Cell cycle.
[11] Michael J. Emanuele,et al. Global Identification of Modular Cullin-RING Ligase Substrates , 2011, Cell.
[12] D. DeAngelo,et al. Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer , 2011, Expert opinion on therapeutic targets.
[13] Anindya Dutta,et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.
[14] Peter G. Smith,et al. The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. , 2010, Genes & cancer.
[15] M. Dimopoulos,et al. Hematology: First-line bortezomib benefits patients with multiple myeloma , 2009, Nature Reviews Clinical Oncology.
[16] D. Lane,et al. Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy , 2009, Cell cycle.
[17] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[18] K. Kinzler,et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 , 2009, Proceedings of the National Academy of Sciences.
[19] D. Xirodimas,et al. Novel substrates and functions for the ubiquitin-like molecule NEDD8. , 2008, Biochemical Society transactions.
[20] E. Lane,et al. Detection of the p53 response in zebrafish embryos using new monoclonal antibodies , 2008, Oncogene.
[21] Kongthawat Chairatvit,et al. Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma , 2007, Molecular and Cellular Biochemistry.
[22] Youngjo Kim,et al. Cdt1 degradation to prevent DNA re-replication: conserved and non-conserved pathways , 2007, Cell Division.
[23] Matthias Dobbelstein,et al. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. , 2006, Cancer research.
[24] D. Lane,et al. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress , 2006, Cell Death and Differentiation.
[25] M. Blagosklonny,et al. Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy , 2004, Cell cycle.
[26] M. Kent,et al. The State of the Art of the Zebrafish Model for Toxicology and Toxicologic Pathology Research—Advantages and Current Limitations , 2003, Toxicologic pathology.
[27] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[28] M. Blagosklonny,et al. Exploiting cancer cell cycling for selective protection of normal cells. , 2001, Cancer research.
[29] M V Chernov,et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.
[30] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[31] R. Perry,et al. Inhibition of RNA synthesis by actinomycin D: Characteristic dose‐response of different RNA species , 1970, Journal of cellular physiology.
[32] M. Westerfield. The zebrafish book : a guide for the laboratory use of zebrafish (Danio rerio) , 1995 .